PMID- 21209383 OWN - NLM STAT- MEDLINE DCOM- 20110509 LR - 20211020 IS - 1522-1490 (Electronic) IS - 0363-6119 (Print) IS - 0363-6119 (Linking) VI - 300 IP - 3 DP - 2011 Mar TI - IkappaBalpha degradation is necessary for skeletal muscle atrophy associated with contractile claudication. PG - R595-604 LID - 10.1152/ajpregu.00728.2010 [doi] AB - The arterial blockage in patients with peripheral arterial disease (PAD) restricts oxygen delivery to skeletal muscles distal to the blockage. In advanced-stage PAD patients, this creates a chronic ischemic condition in the affected muscles. However, in the majority of PAD patients, the muscles distal to the blockage only become ischemic during physical activity when the oxygen demands of these muscles are increased. Therefore, the skeletal muscle of most PAD patients undergoes repeated cycles of low-grade ischemia-reperfusion each time the patient is active and then rests. This has been speculated to contribute to the biochemical and morphological myopathies observed in PAD patients. The current study aimed to determine, using a rodent model, whether repeated hind limb muscle contractions during blood flow restriction to the hind limb muscles increases NF-kappaB activity. We, subsequently, determined whether an increase in NF-kappaB activity during this condition is required for the increased transcription of specific atrophy-related genes and muscle fiber atrophy. We found that hind limb muscle contractions during blood flow restriction to the limb increased NF-kappaB activity, the transcription of specific atrophy-related genes, and caused a 35% decrease in muscle fiber cross-sectional area. We further found that inhibition of NF-kappaB activity, via gene transfer of a dominant-negative inhibitor of kappaBalpha (d.n. IkappaBalpha), prevented the increase in atrophy gene expression and muscle fiber atrophy. These findings demonstrate that when blood flow to skeletal muscle is restricted, repeated cycles of muscle contraction can cause muscle fiber atrophy that requires NF-kappaB-IkappaBalpha signaling. FAU - Hain, Brian A AU - Hain BA AD - Department of Applied Physiology, Univ. of Florida, Gainesville, 32611, USA. FAU - Dodd, Stephen L AU - Dodd SL FAU - Judge, Andrew R AU - Judge AR LA - eng GR - P30 AG028740/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110105 PL - United States TA - Am J Physiol Regul Integr Comp Physiol JT - American journal of physiology. Regulatory, integrative and comparative physiology JID - 100901230 RN - 0 (I-kappa B Proteins) RN - 0 (NF-kappa B) RN - 0 (Nfkbia protein, rat) RN - 0 (RNA, Messenger) RN - 0 (Recombinant Fusion Proteins) RN - 139874-52-5 (NF-KappaB Inhibitor alpha) SB - IM MH - Animals MH - Disease Models, Animal MH - Electric Stimulation MH - Electroporation MH - Gene Expression Regulation MH - Gene Transfer Techniques MH - Hindlimb MH - I-kappa B Proteins/genetics/*metabolism MH - Intermittent Claudication/genetics/*metabolism/pathology/physiopathology MH - Ischemia/genetics/*metabolism/pathology/physiopathology MH - Ligation MH - Male MH - *Muscle Contraction MH - Muscle, Skeletal/blood supply/*metabolism/pathology/physiopathology MH - Muscular Atrophy/genetics/*metabolism/pathology/physiopathology MH - NF-KappaB Inhibitor alpha MH - NF-kappa B/genetics/metabolism MH - RNA, Messenger/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Recombinant Fusion Proteins/metabolism MH - Regional Blood Flow MH - Time Factors MH - Transcription, Genetic PMC - PMC6195647 EDAT- 2011/01/07 06:00 MHDA- 2011/05/10 06:00 PMCR- 2012/03/01 CRDT- 2011/01/07 06:00 PHST- 2011/01/07 06:00 [entrez] PHST- 2011/01/07 06:00 [pubmed] PHST- 2011/05/10 06:00 [medline] PHST- 2012/03/01 00:00 [pmc-release] AID - ajpregu.00728.2010 [pii] AID - R-00728-2010 [pii] AID - 10.1152/ajpregu.00728.2010 [doi] PST - ppublish SO - Am J Physiol Regul Integr Comp Physiol. 2011 Mar;300(3):R595-604. doi: 10.1152/ajpregu.00728.2010. Epub 2011 Jan 5.